Subscribe
hires-illumina-building-entrance-courtesy-of-illumina-inc-
Photo: Courtesy of Illumina, Inc (http://www.illumina.com/company/news-center/multimedia-images.html)
11 April 2023Big PharmaStaff writer

Scientist accuses Illumina of long-running trade secrets plot

Dispute stems from the theft of a data set of ZipCode sequences used in genetic testing |  Plaintiff holds that pharma companies conspired against him | Cornell University claimed that Thermo Fisher misled it into settling a lawsuit in 2017.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.

More on this story

Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York